drugset
Drugs / Flortaucipir F18
last change Jul 2026 re-read 2 minutes ago

Flortaucipir F18

also known as 18F-AV-1451 · 18F-flortaucipir · AV-1451 · 11C-Pittsburgh compound-B · F 18 T807 · F-18 AV 1451 · flortaucipir

Diagnostic / imaging agent

Investigated by
Avid Radiopharmaceuticals · Mayo Clinic · National Institute of Neurological Disorders and Stroke (NINDS) · National Institute on Aging (NIA) · Alzheimer's Association · Alzheimer's Therapeutic Research Institute
+13 more · Boston Children's Hospital · Columbia University · Eli Radiopharma · Kejal Kantarci · Medical College of Wisconsin · National Football League · Neil M Rofsky, MD, MHA · Tammie L. S. Benzinger, MD, PhD · The Cleveland Clinic · University of Alabama at Birmingham · University of Chicago · University of North Carolina, Chapel Hill · University of Southern California

Regulatory milestones approvals, filings & regulatory actions · 1 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Approved US (FDA) TAUVID — 2020-05-28 fda.gov ↗

Trials 27 · a red edge is where a trial was stopped

today
US approved 2020
NCT07580703 · Ph 1 NCT06723015 · Ph 2 NCT03809351 · Ph 1 NCT04263337 · Ph 1 NCT03821857 · Ph 4 NCT03901105 · Ph 3 NCT04080544 · Ph 2 NCT03582488 · Ph 4 NCT03467477 · Ph 2 NCT03322462 · Ph 2 NCT02707978 · Ph 2 NCT03040713 · Ph 1 NCT03052972 · Ph 1 NCT02350634 · Ph 1 NCT02850146 · Ph 1 NCT02736695 · Ph 1 NCT02676843 · Ph 2 NCT03283449 · Ph 1 NCT02512029 · Ph 1 NCT02278354 · Ph 1 NCT02336360 · Ph 1 NCT02278367 · Ph 2 NCT04468347 · Ph 1 NCT02079766 · Ph 2 NCT02051764 · Ph 2 NCT01992380 · Ph 1 NCT04474405 · Ph 0
20142015201620172018201920202021202220232024202520262027202820292030
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT04474405 Aug → Dec 2013 Alzheimer disease Avid Radiopharmaceuticals Completed No outcome recorded
Phase 114 trials
Phase 1 NCT07580703 Apr → Dec 2026 expected Alzheimer disease Eli Radiopharma Recruiting No outcome recorded
Phase 1 NCT03809351 Jul 2020 → Jul 2028 expected Alzheimer disease University of Alabama at Birmingham Recruiting No outcome recorded
Phase 1 NCT04263337 Mar 2020 → Aug 2028 expected brain injury University of North Carolina, Chapel Hill Active not recruiting No outcome recorded
Phase 1 NCT03040713 Apr 2017 → Oct 2018 frontotemporal dementia Avid Radiopharmaceuticals Completed No outcome recorded
Phase 1 NCT03052972 Mar 2017 → Aug 2018 cognitive disorder Avid Radiopharmaceuticals Terminated No outcome recorded
Phase 1 NCT02350634 Nov 2016 → Jun 2017 Alzheimer disease Avid Radiopharmaceuticals Completed No outcome recorded
Phase 1 NCT02850146 Aug 2016 → Sep 2023 cognitive disorder University of Southern California Completed No outcome recorded
Phase 1 NCT02736695 Jul 2016 → Aug 2024 behavioral variant of frontotemporal dementia, primary progressive aphasia Mayo Clinic Completed No outcome recorded
Phase 1 NCT03283449 Feb 2016 → Feb 2025 primary progressive aphasia University of Chicago Completed No outcome recorded
Phase 1 NCT02512029 Oct 2015 → Apr 2017 traumatic brain injury Avid Radiopharmaceuticals Withdrawn No outcome recorded
Phase 29 trials
Phase 2 NCT06723015 Nov 2025 → Aug 2028 expected Alzheimer disease, cognitive impairment with or without cerebellar ataxia Mayo Clinic Enrolling by invitation No outcome recorded
Phase 2 NCT04080544 Jan 2019 → Jun 2022 Alzheimer disease Neil M Rofsky, MD, MHA Completed No outcome recorded
Phase 2 NCT03467477 Mar → Nov 2018 Alzheimer disease Avid Radiopharmaceuticals Completed No outcome recorded
Phase 2 NCT03322462 Nov 2017 → Aug 2018 Alzheimer disease Avid Radiopharmaceuticals Completed No outcome recorded
Phase 2 NCT02707978 Sep 2017 → Sep 2020 Alzheimer disease Tammie L. S. Benzinger, MD, PhD Withdrawn No outcome recorded
Phase 2 NCT02676843 Apr 2016 → Nov 2018 frontotemporal dementia, tauopathy Columbia University Completed No outcome recorded
Phase 2 NCT02278367 Dec 2014 → Jun 2019 Alzheimer disease, depressive disorder, traumatic brain injury Avid Radiopharmaceuticals Completed No outcome recorded
Phase 2 NCT02079766 Jun 2014 → Oct 2015 dementia pugilistica Avid Radiopharmaceuticals Completed No outcome recorded
Phase 2 NCT02051764 May 2014 → Dec 2016 Alzheimer disease Avid Radiopharmaceuticals Terminated No outcome recorded
Phase 31 trial
Phase 3 NCT03901105 Mar → Apr 2019 Alzheimer disease Avid Radiopharmaceuticals Completed No outcome recorded
Phase 42 trials
Phase 4 NCT03821857 Jun 2019 → May 2030 expected Alzheimer disease Mayo Clinic Recruiting No outcome recorded
Phase 4 NCT03582488 Jun 2018 → Sep 2027 expected Lewy body dementia Kejal Kantarci Enrolling by invitation No outcome recorded
Also used as a comparator or background therapy in 2 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT03019536 Background Jan 2017 → Jun 2019 Alzheimer disease Eli Lilly and Company Completed No outcome recorded
Phase 41 trial
Phase 4 NCT04417998 Comparator Jun 2020 → Dec 2023 — Mayo Clinic Completed No outcome recorded

Evidence & citations 10 cited values

Every value below carries the sentence it was read from. 31 sources stand behind the page.

FieldValueCited text
Known as Flortaucipir F18 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02079766 ↗
14

NCT04468347 ↗

NCT03040713 ↗

NCT02051764 ↗

NCT01992380 ↗

NCT03052972 ↗

NCT03322462 ↗

NCT02350634 ↗

NCT04474405 ↗

NCT03019536 ↗

NCT03467477 ↗

NCT02278367 ↗

NCT03901105 ↗

NCT02278354 ↗

NCT02336360 ↗
Known as 11C-Pittsburgh compound-B “18F-Flortaucipir and 11C-Pittsburgh compound-B radioligands will be used for experimental PET imaging of beta-amyloid and neurofibrillary tau pathology” NCT03582488 ↗
Known as 18F-AV-1451 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02676843 ↗
6

NCT04417998 ↗

NCT02512029 ↗

NCT02850146 ↗

NCT06723015 ↗

NCT04080544 ↗

NCT03283449 ↗
Known as 18F-flortaucipir “OBJECTIVE: 18F-flortaucipir (Tauvid™) is an 18F-labeled diagnostic positron emission tomography (PET) radiopharmaceutical, which was developed to detect tau pathology in the brain” PMID 42467182 ↗ Jul 2026
4

NCT07580703 ↗

NCT04263337 ↗

NCT03821857 ↗

NCT03582488 ↗
Known as AV-1451 “No neuroimaging studies have investigated tau deposition in PPA and hence the binding characteristics of AV-1451 (the Tau binding drug used in this study) in PPA are unknown.” NCT02736695 ↗
1

NCT03809351 ↗
Known as F 18 T807 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02707978 ↗
Known as F-18 AV 1451 “Drug: F-18 AV 1451” NCT02736695 ↗
Known as flortaucipir “OBJECTIVE: 18F-flortaucipir (Tauvid™) is an 18F-labeled diagnostic positron emission tomography (PET) radiopharmaceutical, which was developed to detect tau pathology in the brain” PMID 42467182 ↗ Jul 2026
Modality Diagnostic / imaging agent “Test-Retest Reproducibility for the Tau PET Imaging Agent Flortaucipir F 18.” PMID 29284675 ↗ Dec 2017
Route Intravenous “IV injection” NCT01992380 ↗